DelveInsight’s “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Small Cell Lung Cancer Market Forecast
Some of the key facts of the Non-Small Cell Lung Cancer Market Report:
The Non-Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2023, Novocure announced that the LUNAR study, assessing the safety and effectiveness of Tumor Treating Fields (TTFields) alongside standard treatments for stage 4 non-small cell lung cancer (NSCLC) after progression on or following platinum-based therapy, successfully achieved its primary goal.
In January 2023, Daiichi Sankyo has launched the TROPION-Lung07 Phase III trial to assess the efficacy of datopotamab deruxtecan combined with pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
In January 2023, The EMA has validated the Type II variation application for ENHERTU for treating HER2 mutant metastatic non-small cell lung cancer.
According to DelveInsight’s analysis, there were roughly 500,000 new cases of NSCLC in the 7MM in 2022, and this number is projected to increase to about 600,000 by 2032.
In the US for 2023, there are around 200,000 new cases of lung cancer (117,550 in men and 120,790 in women). Statistics typically include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with SCLC accounting for about 10% to 15% of cases and NSCLC making up about 80% to 85%. The most common biomarkers in lung cancer are EGFR (64%), ALK (60%), PD-L1 (48%), ROS1 (46%), BRAF (40%), MET (35%), KRAS (29%), RET (22%), HER2 (21%), and PIK3CA (20%).
The US FDA has approved Merck’s KEYTRUDA (pembrolizumab) for adjuvant treatment after resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC).
Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
The Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Non-Small Cell Lung Cancer market dynamics.
Non-Small Cell Lung Cancer Overview
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is a category of epithelial lung cancer that includes several subtypes with similar treatment approaches and prognoses.
Get a Free sample for the Non-Small Cell Lung Cancer Market Report:
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
Non-Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Non-Small Cell Lung Cancer Epidemiology Segmentation:
The Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Non-Small Cell Lung Cancer
Prevalent Cases of Non-Small Cell Lung Cancer by severity
Gender-specific Prevalence of Non-Small Cell Lung Cancer
Diagnosed Cases of Episodic and Chronic Non-Small Cell Lung Cancer
Download the report to understand which factors are driving Non-Small Cell Lung Cancer epidemiology trends @ Non-Small Cell Lung Cancer Epidemiology Forecast
Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Non-Small Cell Lung Cancer Therapies and Key Companies
Telisotuzumab Vedotin: AbbVie
Ensartinib (X-396): Xcovery
SAR408701: Sanofi
Hyleukin-7 (NT-I7;Efineptakin Alfa): NeoImmune Tech
Avelumab (Bavencio): Merck KGaA and Pfizer
Sitravatinib: Mirati Therapeutics
Trastuzumab deruxtecan: AstraZeneca
DS-1062a: Daiichi Sankyo, Inc.
Durvalumab: Parexel
Sacituzumab Govitecan-hziy (SG): Gilead Sciences
Pembrolizumab: Merck Sharp & Dohme LLC
Domvanalimab: Arcus Biosciences, Inc.
ONO-4538: Ono Pharmaceutical Co. Ltd
M7824: EMD Serono
Retifanlimab: Incyte Corporation
Lenvatinib: Eisai Inc.
To know more about Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment
Non-Small Cell Lung Cancer Market Drivers
Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market
The development of therapies targeting specific mutations are expected to dominate the upcoming market
Non-Small Cell Lung Cancer Market Barriers
Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast
Scope of the Non-Small Cell Lung Cancer Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Small Cell Lung Cancer Market Access and Reimbursement
Discover more about therapies set to grab major Non-Small Cell Lung Cancer market share @ Non-Small Cell Lung Cancer Treatment Market
Table of Contents
1. Non-Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for Non-Small Cell Lung Cancer
3. SWOT analysis of Non-Small Cell Lung Cancer
4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Non-Small Cell Lung Cancer Market Overview at a Glance
6. Non-Small Cell Lung Cancer Disease Background and Overview
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Small Cell Lung Cancer
9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices
10. Non-Small Cell Lung Cancer Unmet Needs
11. Non-Small Cell Lung Cancer Emerging Therapies
12. Non-Small Cell Lung Cancer Market Outlook
13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2019–2032)
14. Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. Non-Small Cell Lung Cancer Market Drivers
16. Non-Small Cell Lung Cancer Market Barriers
17. Non-Small Cell Lung Cancer Appendix
18. Non-Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
